Efficacy of bone marrow mesenchymal stem cells in treatment of lower limb ischemic disease: Meta-analysis / 中国介入影像与治疗学

ABSTRACT

Objective: To evaluate the efficacy of bone marrow mesenchymal stem cells (BMSCs) in the treatment of lower limb ischemic disease using Meta-analysis. Methods The literature of clinical controlled trials concerning BMSCs in treatment of lower limb ischemic disease were retrieved by searching PubMed, EMbase and Cochrane Library databases. Literature screening and data extraction were carried out according to the inclusion and exclusion criteria. Meta-analysis was conducted by using RevMan 5.3 software. The amputation rate, amputation-free survival rate, ankle-brachial index, ulcer healing rate, pain score and pain-free walking distance were compared between BMSCs group and control group. Results A total of 5 articles were included. Meta-analysis showed that ankle-brachial index (mean difference [MD]=0.15, 95%CI [0.12,0.18], P<0.000 01), pain score (MD=-1.38, 95%CI [-1.65, -1.11], P<0.000 01), pain-free walking distance (MD=202.20, 95%CI [154.30, 250.10], P<0.000 01) and ulcer healing rate (relative risk [RR]=1.42, 95%CI [0.82, 2.46], P=0.021) were significantly improved in BMSCs group than those in control group. The amputation rate (RR=0.52, 95%CI [0.24, 1.10], P=0.09), amputation-free survival rate (RR=1.09, 95%CI [0.98, 1.21], P=0.12) demonstrated no significant differences between BMSCs and control group. Conclusion: Meta-analysis shows no advantage of BMSCs therapy on the amputation rate and amputation-free survival rate in patients with lower limb ischemic disease, but BMSCs treatment is more effective in improving clinical symptoms of patients.